
Quarterly report 2025-Q3
added 02-21-2026
BeyondSpring Net Debt 2011-2026 | BYSI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt BeyondSpring
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -107 M | -34 M | - | - | -11.5 M | -10.8 M | -392 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -392 K | -107 M | -32.6 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Alector
ALEC
|
-47.4 M | $ 2.08 | -14.4 % | $ 214 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Altimmune
ALT
|
-35.2 M | $ 4.2 | -2.67 % | $ 298 M | ||
|
Apellis Pharmaceuticals
APLS
|
-311 M | $ 20.24 | -3.44 % | $ 2.55 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.8 | 1.87 % | $ 4.36 M | ||
|
Aprea Therapeutics
APRE
|
-130 M | $ 0.88 | -3.72 % | $ 3.18 M | ||
|
Aptevo Therapeutics
APVO
|
-3.28 M | $ 7.2 | -1.64 % | $ 1.99 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Aquestive Therapeutics
AQST
|
-26 M | $ 4.1 | 2.37 % | $ 356 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-208 M | $ 8.35 | 1.46 % | $ 225 M | ||
|
Ardelyx
ARDX
|
136 M | $ 6.37 | -2.75 % | $ 1.54 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
argenx SE
ARGX
|
-89.9 M | $ 756.71 | -1.33 % | $ 25 B | ||
|
Armata Pharmaceuticals
ARMP
|
54.6 M | $ 10.91 | 1.58 % | $ 394 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 25.33 | -6.1 % | $ 3.22 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Artelo Biosciences
ARTL
|
-531 K | $ 1.15 | -3.36 % | $ 2.32 M | ||
|
Arvinas
ARVN
|
-141 M | $ 12.97 | -2.3 % | $ 920 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 61.74 | -2.42 % | $ 8.26 B | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 231.56 | -0.83 % | $ 5 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.39 | -1.63 % | $ 8.16 B | ||
|
Actinium Pharmaceuticals
ATNM
|
-72.3 M | $ 1.17 | -0.85 % | $ 35.2 M | ||
|
Atossa Therapeutics
ATOS
|
-39.6 M | $ 4.39 | -0.9 % | $ 553 M | ||
|
Atara Biotherapeutics
ATRA
|
31.1 M | $ 5.01 | -7.47 % | $ 37.5 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
-26.8 M | $ 14.14 | -0.21 % | $ 1.9 B | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.68 | -1.75 % | $ 429 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Atea Pharmaceuticals
AVIR
|
-63.1 M | $ 4.69 | 0.21 % | $ 395 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
-22.2 M | $ 4.54 | 2.44 % | $ 387 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Axon Enterprise
AXON
|
-404 M | $ 570.5 | 5.18 % | $ 43.2 B | ||
|
Axsome Therapeutics
AXSM
|
-205 M | $ 162.28 | -0.98 % | $ 8.07 B | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.56 | -0.58 % | $ 16.1 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B |